ZVRA Stock Analysis: Buy, Sell, or Hold?
ZVRA - Zevra Therapeutics, Inc. Common Stock
$13.98
0.17 (1.23%)
▲
5d:
+5.67%
30d:
+28.49%
90d:
+48.57%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When ZVRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called ZVRA this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ZVRA is fairly valued with market pricing in 4.5% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: ZVRA is fairly valued with market pricing in 4.5% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$12.70
Based on 0.9% avg growth
INTRINSIC VALUE TODAY
$7.89
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZVRA is currently trading at $13.98, which is considered extended relative to its 30-day fair value range of $10.97 to $13.26. From a valuation perspective, the stock is trading at a premium (Forward PE: 11.7) compared to its historical average (10.2). At these levels, the market is pricing in 4.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ZVRA is in a strong uptrend. Immediate support is located at $12.48, while resistance sits at $14.58.
Market Sentiment: ZVRA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $27.89 (+99.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ZVRA is in a strong uptrend. Immediate support is located at $12.48, while resistance sits at $14.58.
Market Sentiment: ZVRA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $27.89 (+99.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$10.97 -
$13.26
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
58.1%
Protect Your Profits
Holding ZVRA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+5.4% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 99.5% below Wall St target ($27.89)
- NEUTRAL: Market pricing in 4.5% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$10.97 -
$13.26
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$12.48
Resistance Level
$14.58
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.70
Wall Street Target
$27.89
(+99.5%)
Revenue Growth (YoY)
77.5%
Profit Margin
101.6%
Valuation Premium vs History
+4.5% premium
PE vs Historical
11.7 vs 10.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.5%
(market-implied from PE analysis)
1-Year Target
$14.61
(+5%)
2-Year Target
$15.27
(+9%)
3-Year Target
$15.95
(+14%)
3-Yr Target (if PE normalizes)
(PE: 12→10)
PE COMPRESSION
$13.91
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: -2.3%)
$24.26
(+74%)
Base:
(SPY PE: 11.7, Growth: -2.3%)
$13.03
(-7%)
Bear:
(PE: 9.9, Growth: -2.3%)
$11.08
(-21%)
📈
Valuation based on Current Earnings
Trailing PE: 6.87 | Current EPS (TTM): $2.01
Bull Case
$9.03
(-35%)
Analyst growth -40.5%, PE expands to 7.6
Base Case
$8.21
(-41%)
Market implied -40.5%, PE stable at 6.9
Bear Case
$9.39
(-33%)
Severe decline -20.0%, PE contracts to 5.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 05, 2026 12:11 AM ET
Data refreshes hourly during market hours. Next update: 1:11 AM
Data refreshes hourly during market hours. Next update: 1:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZVRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Joshua Schafer
SELL
10500 shares
2026-02-03
Timothy J Sangiovanni
SELL
3000 shares
2026-02-03
Neil F Mcfarlane
SELL
91000 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 55 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 63 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 63 BUY |
Advanced ZVRA Option Strategies
Professional options setups generated by AI based on today's ZVRA price and gamma walls.
